Achievement of English National Service Framework lipid-lowering goals: Pooled data from recent comparative treatment trials of statins at starting doses

International Journal of Clinical Practice

Volumn 59, Issue 10, 2005, Pages 1171-1177

  Hobbs, F D Richard ^a   Southworth, H ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Lipid targets; NSF; Start dose; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED KINGDOM; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; META ANALYSIS; MIDDLE AGED; PRACTICE GUIDELINE;

ADULT; AGED; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33644842991     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00646.x     Document Type: Article

References (38)

1. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
2. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results AFCAPS/Texcaps. JAMA 1998; 279: 1615-22.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
5. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
6. De Backer G, Ambrosioni E, Borch-Johnsen K et al. for the Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
9. Cannon CP, Braunwald E, Mccabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
10. Sever PS, Dahlof B, Poulter NR et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
11. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
12. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
13. Pearson TA, Laurora IM. Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP). Circulation 1997; 96 (Suppl. 8): A361.
14. Durrington P. The human and economic costs of undertreatment with statins. Int J Clin Pract 2002; 56: 357-68.
15. Frolkis JP, Pearce GL, Nambi V et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002; 113: 625-9.
16. Sacks FM. Adherence to statin therapy: Why aren't we doing better? Am J Med 2002; 113: 685-6.
17. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998; 279: 1458-62.
18. Sueta CA, Chowdhury M, Boccuzzi SJ et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-7.
19. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-10.
20. Muls E, De Backer G, De Bacquer D et al. LIPI-Watch, a Belgian/ Luxembourg survey on achievement of European Atherosclerosis Society lipid levels. Clin Drug Invest 2000; 19: 219-29.
21. Sueta CA, Petkun WM, Hart PA et al. Recommended management of hyperlipidemia and heart failure: Are we following the guidelines? Circulation 1997; 96 (Suppl. 1): 1-66.
22. Blasetto J, Stein E, Brown WV et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91 (Suppl. 5A): 3C-10C.
23. Shepherd J, Hunninghake DB, Barter P et al. Guidelines for lowering lipids to reduce coronary heart disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003; 91 (Suppl. 5A): 11C-17C.
24. Jones PH, Davidson MH, Stein EA et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
25. Mckenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: Results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98.
26. National Health Service. National Service Framework for Coronary Heart Disease. Department of Health, London, England, 2000. http://www.doh.gov.uk/nsf/coronary.htm.
27. Boyle R. DoH explains thinking behind national service framework for coronary heart disease. BMJ 2000; 321: 1083.
28. Davidson M, Ma P, Stein EA et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75.
29. Schwartz GG, Bolognese MA, Tremblay BP et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial. Am Heart J 2004; 148 (1): E4.
30. Olsson AG, Istad H, Luurila O et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044-51.
31. Paoletti R, Fahmy M, Mahla G et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383-90.
32. Brown WV, Bays HE, Hassman DR et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036-43.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
34. Hulley SB. The US National Cholesterol Education Program. Adult treatment guidelines. Drugs 1988; 36: 100-4.
35. Peters JR, Quiter ES, Brekke ML et al. The Eating Pattern Assessment Tool: A simple instrument for assessing dietary fat and cholesterol intake. J Am Diet Assoc 1994; 94: 1008-13.
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
37. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
38. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002; 176: 211-5.